Idorsia
Daniel Ritz has extensive work experience in the pharmaceutical industry. Daniel worked at Idorsia Pharmaceuticals Ltd from 2017 until present as a Senior Director and Senior Group Leader Biology. Prior to that, they worked at Actelion from 2005 to 2017, holding various roles including Senior Group Leader Anti-Infectives Biology, Senior Lab Head Anti-Infectives Biology, and Lab Head Anti-Infectives Biology. Before joining Actelion, they were a Senior Research Scientist at Cubist Pharmaceuticals from 2002 to 2005. Daniel started their career in 1996 as a Postdoctoral Fellow at Harvard Medical School, where they worked until 2002.
Daniel Ritz attended Kanti Alpenquai, but no specific start or end year or degree is provided for this institution. Daniel then went on to study at ETH Zürich, where they obtained a degree in Biochemistry (Dipl Natw) from 1985 to 1991, and later pursued a Dr. sc nat (Doctorate in Natural Sciences) in Microbiology from 1991 to 1996.
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.